Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
epigallocatechin-3-gallate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| (2)-epigallocatechin-3-gallate (EGCG) | EXPERIMENTAL | Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o. |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| (2)-epigallocatechin-3-gallate (EGCG) | DRUG | Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600) |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Chorea Huntington (CAG repeats \>39) * UHDRS TFC \>5 * ≥18 years of age * Readiness and ability to take oral medication * Normal liver function laboratory test * Stable concomitant medication regimen \> 4 weeks prior to Baseline * Motivation for women with childbearing potenti...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
Epigallocatechin-3-gallate is an investigational small molecule being studied for the treatment of Huntington disease. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed clinical trial with 54 participants, but it is not yet approved for any use.
Pulmonx Corporation, traded on the NASDAQ under the ticker LUNG, is developing epigallocatechin-3-gallate. The company is conducting clinical research on this drug for Huntington disease, a neurological condition. The drug is currently in Phase 2 development.
Epigallocatechin-3-gallate is in Phase 2 clinical development for Huntington disease. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug has completed one Phase 2 trial, and no active trials are currently listed for this asset.
Epigallocatechin-3-gallate has been studied in one completed clinical trial, identified as NCT01357681. This Phase 2 study, titled "Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)," enrolled 54 participants in Germany. The trial was randomized, double-blind, and placebo-controlled, and it included biomarker selection.
Yes, epigallocatechin-3-gallate is also known as EGCG. The clinical trial NCT01357681, which studied this drug in Huntington disease, used the abbreviation EGCG in its title. The drug is a small molecule being developed by Pulmonx Corporation for this neurological condition.